Advertisement

Topics

Knight Reports Second Quarter 2015 Results

20:00 EDT 11 Aug 2015 | Marketwired

MONTREAL, QUEBEC -- (Marketwired) -- 08/12/15 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, today reported its second quarter ended June 30, 2015 financial results.

Second Quarter 2015 Highlights

Subsequent to the Quarter Ended June 30, 2015 Highlights:

Second Quarter 2015 Financial Results Reported in Canadian Dollars

The Company's financial statements for the period ended June 30, 2015 have been prepared in accordance with IAS 34, Interim Financial Reporting.

For the quarter ended June 30, 2015, the Company reported revenues of $333 thousand and net income of $8.5 million. For the six-month period ended June 30, 2015, the Company reported revenues of $580 thousand and net income of $22.3 million. As at June 30, 2015, the Company had $437.0 million in cash and marketable securities and 93,095,823 common shares outstanding.

"During and subsequent to the quarter, we added a total of nine innovative specialty pharmaceuticals, OTC products and medical devices to our pipeline thanks to the relentless execution of our proven strategies," said Jonathan Ross Goodman, President and CEO of Knight Therapeutics Inc. "Looking ahead, we plan to continue building our pipeline while also focusing our attention on the re-launch Neuragen® in Canada."

Conference Call Notice

Knight will host a conference call to discuss its second quarter results today at 8:30 am ET. Investors and other interested parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).

A taped replay of the conference call will be available from today at 11:30 a.m. ET until Wednesday, September 9, 2015 at 11:59 p.m. ET. To access the replay, please call 1-800-585-8367 or 416-621-4642 and use access code 47058125.

Notice of Third Quarter 2015 Results

Knight expects to release its third quarter 2015 financial results on the morning of Wednesday, November 11, 2015. Knight expects to hold a conference call at 8:30 am ET on the morning of the release. All interested parties are cordially invited to attend. Investors and other interested parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for the Company and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in the Company's Annual Report and in the Company's Annual Information Form for the year ended December 31, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Knight Therapeutics Inc.

INTERIM CONSOLIDATED BALANCE SHEETS

As at

(in Canadian dollars)

(unaudited)

Knight Therapeutics Inc.

INTERIM CONSOLIDATED STATEMENTS OF INCOME

(in Canadian dollars)

(unaudited)

Knight Therapeutics Inc.

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in Canadian dollars)

(unaudited)

Knight Therapeutics Inc.

(in Canadian dollars)

(unaudited)

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Knight Therapeutics Inc.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

(in Canadian dollars)

(unaudited)

Contacts: Knight Therapeutics Inc. Jeffrey Kadanoff, P.Eng., MBA Chief Financial Officer 514-484-GUD1 (4831) 514-481-4116 (FAX) NEXT ARTICLE

More From BioPortfolio on "Knight Reports Second Quarter 2015 Results "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...